Biogen (BIIB) Exchange Rate Effect (2009 - 2026)
Biogen (BIIB) posted quarterly Exchange Rate Effect of -$3.4 million for Q2 2026, down 104.98% year-over-year from $68.3 million in Q2 2025, and up 81.11% quarter-over-quarter from -$18.0 million in Q1 2026.
Biogen (BIIB) Exchange Rate Effect (2009 - 2026) Analysis & Trends
Biogen's Exchange Rate Effect history runs 18 years deep, the most recent figure standing at -$3.4 million for Q2 2026.
- In Q2 2026, Exchange Rate Effect fell 104.98% year-over-year to -$3.4 million; the TTM figure through Jun 2026 stood at -$22.1 million (down 131.3% YoY), while the FY2025 annual figure was $101.9 million, up 250.52% from the prior year.
- Exchange Rate Effect for Q2 2026 stood at -$3.4 million, up from -$18.0 million in the prior quarter.
- The five-year high for Exchange Rate Effect was $68.3 million in Q2 2025, with the low at -$74.4 million in Q4 2024.
- The 5-year median for Exchange Rate Effect is -$3.8 million (2023), against an average of -$433333.3.
- The sharpest annual moves came in 2022 and 2025: Exchange Rate Effect sank 525.0% in 2022, then surged 642.06% in 2025.
- Biogen's Exchange Rate Effect stood at $67.2 million in 2022, then slipped by 28.72% to $47.9 million in 2023, then sank by 255.32% to -$74.4 million in 2024, then jumped by 103.36% to $2.5 million in 2025, then tumbled by 236.0% to -$3.4 million in 2026.
- Business Quant data shows BIIB's Exchange Rate Effect at -$3.4 million in Q2 2026, -$18.0 million in Q1 2026, and $2.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.53 Bn | 631.77 Bn | 17.26 Bn | 5.00 Mn |
| 2 | AbbVie | 469.73 Bn | 463.16 Bn | 12.70 Bn | -7.00 Mn |
| 3 | Merck | 376.02 Bn | 368.88 Bn | 12.21 Bn | -37.00 Mn |
| 4 | Novartis Ag | 303.27 Bn | 295.58 Bn | 11.24 Bn | -18.00 Mn |
| 5 | Astrazeneca | 257.79 Bn | 252.89 Bn | 12.86 Bn | 9.00 Mn |
| 6 | Amgen | 236.51 Bn | 222.53 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 182.32 Bn | 179.14 Bn | 6.22 Bn | -19.00 Mn |
| 8 | Pfizer | 159.52 Bn | 147.82 Bn | 10.94 Bn | -4.00 Mn |
| 9 | Gsk | 106.18 Bn | 102.01 Bn | 8.24 Bn | - |
| 10 | Biogen | 32.14 Bn | 30.86 Bn | 1.96 Bn | -3.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.40 Mn |
| Jun 30, 2026 | -3.40 Mn |
| Mar 31, 2026 | -18.00 Mn |
| Mar 31, 2026 | -18.00 Mn |
| Dec 31, 2025 | 2.50 Mn |
| Dec 31, 2025 | 2.50 Mn |
| Sep 30, 2025 | -3.20 Mn |
| Sep 30, 2025 | -3.20 Mn |
| Jun 30, 2025 | 68.30 Mn |
| Jun 30, 2025 | 68.30 Mn |
| Mar 31, 2025 | 34.30 Mn |
| Mar 31, 2025 | 34.30 Mn |
| Dec 31, 2024 | -74.40 Mn |
| Dec 31, 2024 | -74.40 Mn |
| Sep 30, 2024 | 42.40 Mn |
| Sep 30, 2024 | 42.40 Mn |
| Jun 30, 2024 | -12.60 Mn |
| Jun 30, 2024 | -12.60 Mn |
| Mar 31, 2024 | -23.10 Mn |
| Mar 31, 2024 | -23.10 Mn |